Omidenepag isopropyl - Generic Drug Details

✉ Email this page to a colleague

What are the generic drug sources for omidenepag isopropyl and what is the scope of freedom to operate?

Omidenepag isopropyl is the generic ingredient in one branded drug marketed by Visiox Pharma and is included in one NDA. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Omidenepag isopropyl has one hundred and twenty-nine patent family members in thirty-two countries.

One supplier is listed for this compound.

Summary for omidenepag isopropyl

International Patents:	129
US Patents:	11
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	22
Clinical Trials:	1
Patent Applications:	44
What excipients (inactive ingredients) are in omidenepag isopropyl?	omidenepag isopropyl excipients list
DailyMed Link:	omidenepag isopropyl at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for omidenepag isopropyl

Generic Entry Date for omidenepag isopropyl^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: NEW CHEMICAL ENTITY Dosage: SOLUTION;OPHTHALMIC

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for omidenepag isopropyl

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Santen Pharmaceutical Asia Pte. Ltd.	Phase 4

See all omidenepag isopropyl clinical trials

Pharmacology for omidenepag isopropyl

Drug Class	Prostaglandin E2 Receptor Agonist
Mechanism of Action	Prostaglandin E2 Receptor Agonists

Anatomical Therapeutic Chemical (ATC) Classes for omidenepag isopropyl

S01EX	Other antiglaucoma preparations
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for omidenepag isopropyl

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Visiox Pharma	OMLONTI	omidenepag isopropyl	SOLUTION;OPHTHALMIC	215092-001	Sep 22, 2022		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Visiox Pharma	OMLONTI	omidenepag isopropyl	SOLUTION;OPHTHALMIC	215092-001	Sep 22, 2022		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y	Y		⤷ Sign Up
Visiox Pharma	OMLONTI	omidenepag isopropyl	SOLUTION;OPHTHALMIC	215092-001	Sep 22, 2022		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for omidenepag isopropyl

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Japan	WO2010113957	緑内障の治療又は予防のための医薬組成物	⤷ Sign Up
Mexico	2020003133	COMPOSICION FARMACEUTICA QUE CONTIENE COMPUESTO DE ACIDO PIRIDILAMINOACETICO. (PHARMACEUTICAL COMPOSITION CONTAINING PYRIDYLAMINO ACETIC ACID COMPOUND.)	⤷ Sign Up
European Patent Office	2264009	COMPOSÉ D'ACIDE PYRIDYLAMINOACÉTIQUE (PYRIDYLAMINOACETIC ACID COMPOUND)	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.